2024 - Spatial Visualization of Capsid-Dependent Viral Tropism using RNAscopeTM ISH Technology
Date2024-09-18
Deadline2024-09-18
VenueONLINE-VIRTUAL, USA - United States
KeywordsLife Sciences; Pharmaceutical; Fundamental Research
Topics/Call fo Papers
The RNAscope in situ hybridization (ISH) assay provides spatial visualization of biodistribution and efficacy of adeno-associated virus (AAV) vector-mediated gene delivery.
Low transduction efficiency, off-target tropism and overcoming pre-existing immunogenicity are some challenges presented when developing AAV-based gene therapeutics. Capsid engineering can improve transduction efficiency, cellular and tissue tropism and overcome immunogenicity. Therefore, the selection of engineered capsids that demonstrate desirable properties is critical to making informed decisions for AAV-based gene therapies.
The RNAscope ISH assay guides the selection of the optimal capsid, demonstrates improved and selective transduction of the viral vector to safely deliver cargo intracellularly and improves tissue tropism with functional efficiency as well as persistence over time.
In this webinar, the attendees will also learn about Bio-Techne’s flexible, scalable multi-omic service offerings with expert end-to-end RNAscope Professional Assay Services (PAS), including early access to new assay capabilities.
Register for this webinar today to know how capsid engineering and the RNAscope ISH assay can dramatically enhance the specificity, efficacy and safety of gene therapies.
Keywords: Gene Therapy, Genomics, Proteomics, Virology, AAV, Cell & Gene Therapies, AAV Manufacturing, Basic Research, AAV Capsid, CGT
Low transduction efficiency, off-target tropism and overcoming pre-existing immunogenicity are some challenges presented when developing AAV-based gene therapeutics. Capsid engineering can improve transduction efficiency, cellular and tissue tropism and overcome immunogenicity. Therefore, the selection of engineered capsids that demonstrate desirable properties is critical to making informed decisions for AAV-based gene therapies.
The RNAscope ISH assay guides the selection of the optimal capsid, demonstrates improved and selective transduction of the viral vector to safely deliver cargo intracellularly and improves tissue tropism with functional efficiency as well as persistence over time.
In this webinar, the attendees will also learn about Bio-Techne’s flexible, scalable multi-omic service offerings with expert end-to-end RNAscope Professional Assay Services (PAS), including early access to new assay capabilities.
Register for this webinar today to know how capsid engineering and the RNAscope ISH assay can dramatically enhance the specificity, efficacy and safety of gene therapies.
Keywords: Gene Therapy, Genomics, Proteomics, Virology, AAV, Cell & Gene Therapies, AAV Manufacturing, Basic Research, AAV Capsid, CGT
Other CFPs
- Accelerating Neurodegenerative Clinical Drug Development with AI
- Next-Generation CAR-T Therapies: Optimizing Opportunities and Operationalizing Patient-Centric Oncology Clinical Trials
- Advancing MS Clinical Trials: Integrating Medical Imaging, Precision Motion Analysis, and eCOA Data for Enhanced Outcomes
- Enhancing NGS Sample Preparation from Sample to the Sequencer
- Advancing Oncology Care: The Evolving Role of Diagnostic Labs in Biomarker-Driven Therapies
Last modified: 2024-08-09 03:25:12